USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
APAC Biosimilar Market, Forecast 2025
Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
10-Jan-2018
Asia Pacific
Market Research
P9A3-01-00-00-00
LS00279-AP-MT_21441
$4,950.00
Special Price $3,712.50 save 25 %
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.
Research Highlights
The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.
Key Features
The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.
Key Issues Addressed
- What is the current scenario of the biosimilars market in APAC, and how far will it grow?
- What are the key factors driving the market, and what are the barriers that need to be resolved?
- Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
- Who are the key market participants involved, and where do they stand?
- What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market?
- What is the future of the biosimilars market in Asia?
Purpose of the Experiential Study
5 Step Process to Transformational Growth
Scope and Segmentation
Key Questions This Study Will Answer
Key Findings
Biosimilars—Gateway to Success
Trends in Evolving Biopharmaceuticals Market
Biosimilars Ecosystem—Industry Convergence Map
Ecosystem Partnerships
Disruptive Trends in the Changing Market Landscape
Key Regions
Six Big Market Themes for Global Biosimilars Market
Market Overview
Key Challenges in the Biosimilars Market
Biosimilars Market—Timeline
Market Segmentation by Therapeutic Areas
Trends in Global Biosimilars Market
Global Biosimilar Patenting Trends
Areas Impacting Biosimilars Adoption
Attributes Impeding Physician Adoption of Biosimilars
Drivers and Restraints
Impact Mapping of Drivers and Restraints
Market Snapshot—Biosimilars Market
Percent Revenue Forecast by Region
Revenue Forecast
Revenue Forecast by Molecule Type
Revenue Forecast Discussion
Major Growth Opportunities
Growth Opportunity 1—mAb Biosimilars for Cancer
Growth Opportunity 2—Insulin Glargine Biosimilars for Diabetes
Growth Opportunity 3—mAb Biosimilars for Rheumatoid Arthritis
Strategic Imperatives for Success and Growth
Trastuzumab Biosimilars—Key Participants
Trastuzumab Biosimilars—Revenue Forecast
Trastuzumab Biosimilars—Adoption Rate and Patient Population
Trastuzumab Biosimilars—Price and Discounts
Bevacizumab Biosimilar—Key Participants
Bevacizumab Biosimilar—Revenue Forecast
Bevacizumab Biosimilar—Adoption Rate and Patient Population
Bevacizumab Biosimilar—Price and Discounts
Insulin Glargine Biosimilar—Key Participants
Insulin Glargine Biosimilar—Revenue Forecast
Insulin Glargine Biosimilar—Adoption Rate and Patient Population
Insulin Glargine Biosimilar—Price and Discounts
Etanercept Biosimilar—Key Participants
Etanercept Biosimilar—Revenue Forecast
Etanercept Biosimilar—Adoption Rate and Patient Population
Etanercept Biosimilar—Price and Discounts
Infliximab Biosimilar—Key Participants
Infliximab Biosimilar—Revenue Forecast
Infliximab Biosimilar—Adoption Rate and Patient Population
Infliximab Biosimilar—Price and Discounts
Pipeline for Adalimumab Biosimilar—Key Participants
Adalimumab Biosimilar—Revenue Forecast
Adalimumab Biosimilar—Adoption Rate and Patient Population
Adalimumab Biosimilar—Price and Discounts
APAC—A Lucrative Market for Biosimilars
APAC—Regulatory Authorities
APAC Biosimilars—Game-changing Companies
Patent Expiry for Blockbuster Bio-pharmaceuticals
APAC—Future of Biosimilars
APAC—Market Analysis
Transformation of Industry Ecosystem
Key Factors for New Entrants
Interchangeability
Interchangeability (continued)
Regional Hot Spots
Country Attractiveness
Key Companies to Watch
Mergers, Acquisitions, and Partnerships Assessment
Mergers, Acquisitions, and Partnerships Assessment (continued)
Strategies for Foreign Participants in APAC
Factors Influencing Uptake of Biosimilars in APAC
Factors Influencing Uptake of Biosimilars in APAC—Discussion
Physicians, Patients, and Pharmacists—Perceptions and Concerns
Revenue Forecast
Revenue Forecast Discussion
Market Analysis
Snapshot of Market Participants
Regulatory Environment
Strategic Imperatives for China—Key Trends
Revenue Forecast
Revenue Forecast Discussion
Snapshot of Market Participants
Regulatory Environment
Strategic Imperatives for India—Key Trends
Growth Potential of Key Segments in Bio-tech in India
Revenue Forecast
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Snapshot of Market Participants
Regulatory Environment
Regulatory Environment (continued)
Strategic Imperatives for South Korea—Key Trends
Revenue Forecast
Revenue Forecast Discussion
Snapshot of Market Participants
Regulatory Environment
Regulatory Environment (continued)
Strategic Imperatives for Japan—Key Trends
Revenue Forecast
Revenue Forecast Discussion
Snapshot of Market Participants
Regulatory Environment
Strategic Imperatives for Australia—Key Trends
Visioning Scenarios for the Biosimilars Market
Visioning Scenarios for the Biosimilars Market (continued)
Visioning Scenarios for the Biosimilar Market (continued)
Visioning Scenarios for the Biosimilars Market (continued)
Business Model Essentials
5 Competitive Keys for Success
Future of Biosimilars in APAC
Legal Disclaimer
List of Exhibits
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
List of Exhibits (continued)
Global Regulatory Landscape
Global Regulatory Landscape Discussion
Regulations and their Impact on the Biosimilars Market
Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars
Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars (continued)
Biosimilars are Not Generics—A Comparison Between Generics, Biologics, and Biosimilars (continued)
Biologics and Biosimilars—Manufacturing Processes
Development Process and Technical Requirements for BiosimilarsProduction process and technical needs are complex.
Timeline for Development of a Biosimilar Medicine
Value Chain Analysis—Development of a Biosimilar
Big Pharma Companies (Innovators) Vs Biotech Firms Vs Generic Manufacturers
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Highlights
The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.
Key Features
The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeuti
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Lightbox Content | World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019 |
| Author | Sanjeev Kumar |
| WIP Number | P9A3-01-00-00-00 |
| Is Prebook | No |